Publications
“Analysis of Peptides using Asymmetrical Flow Field-Flow Fractionation”, Ryan R. Manning, Ryan E. Holcomb, Derrick S. Katayama, Robert W. Payne, Joshua M. Stillahn, Charles S. Henry, and Mark Cornell Manning, J. Pharm. Sci. 2021, 110: 3969-3972.
“Role of Buffers in Protein Formulations”, Teddy J. Zbacnik, Ryan E. Holcomb, Derrick S. Katayama, Brian M. Murphy, Robert W. Payne, Richard C. Coccaro, Gabriel J. Evans, James E. Matsuura, Charles S. Henry, and Mark Cornell Manning, J. Pharm. Sci. 2017, 106: 713-733.
“Structural Characteristics of Short Peptides in Solution”, Satoshi Ohtake, Yoshiko Kita, Robert W. Payne, and Mark Cornell Manning, and Tsutomu Arakawa, Protein Peptide Lett. 2013, 20: 1308-1326.
“Stability of Lyophilized Sucrose Formulations of an IgG1: Subvisible Particle Formation”, Janice M. Davis, Ning Zhang, Robert W. Payne, Brian M. Murphy, Ahmad M. Abdul-Fattah, James E. Matsuura, Alan C. Herman and Mark Cornell Manning, Pharm. Dev. Technol. 2013, 18: 883-896.
“Structure, Stability, and Mobility of a Lyophilized IgG1 Monoclonal Antibody as Determined by Second Derivative Infrared Spectroscopy”, Brian M. Murphy, Ning Zhang, Robert W. Payne, Janice M. Davis, Ahmad M. Abdul-Fattah, James E. Matsuura, Alan C. Herman and Mark Cornell Manning, J. Pharm. Sci. 2012, 101: 81-91.
“Product Development Issues with PEGylated Proteins”, Robert W. Payne, Brian M. Murphy, and Mark Cornell Manning, Pharm. Dev. Technol. 2011, 16: 423-440.
“Chemical Instability in Peptide and Protein Pharmaceuticals”, Elizabeth M. Topp, Lei Zhang, Hong Zhao, Robert W. Payne, Gabriel J. Evans, and Mark Cornell Manning, in: Formulation and Process Development Strategies for Manufacturing of a Biopharmaceutical (F. Jameel and S. Hershenson, Eds.), 2010, 41-67.
“Protein Stability during Bioprocessing”, Mark Cornell Manning, Gabriel J. Evans, and Robert W. Payne, in: Formulation and Process Development Strategies for Manufacturing of a Biopharmaceutical (F. Jameel and S. Hershenson, Eds.), 2010, 605-624.
“Prediction of Aggregation Propensity from Primary Sequence Information”, Mark Cornell Manning, Gabriel J. Evans, Cody M. Van Pelt, and Robert W. Payne, in: Formulation and Process Development Strategies for Manufacturing of a Biopharmaceutical (F. Jameel and S. Hershenson, Eds.), 2010, 329-347.
“Stability of Protein Pharmaceuticals: An Update”, Mark Cornell Manning, Danny K. Chou, Brian M. Murphy, Robert W. Payne, and Derrick S. Katayama, Pharm. Res. 2010, 27: 544-575.
“Tools to Enhance Membrane Protein Crystallization”, W. William Wilson, Gregg Whited, Robert W. Payne, Charles Henry, David H. Johnson, and Larry DeLucas, Current Topics in Membranes 2009, 63: 151-178.
“Peptide Formulation: Challenges and Strategies”, Robert W. Payne and Mark Cornell Manning, Innov. Pharm. Technol. Spring 2009, 28: 64-68.
“Second Virial Coefficient Determination of a Therapeutic Peptide by Self-Interaction Chromatography”, Robert W. Payne, Rajiv Nayar, Ralph Tarantino, Sam Del Terzo, John Moschera, Jie Di, David Heilmann, Brian Bray, Mark Cornell Manning, and Charles S. Henry, Biopolymers (Peptide Science) 2006, 84: 527-533.
“Colloidal Behavior of Proteins: Effects of the Second Virial Coefficient on Solubility, Crystallization, and Aggregation of Proteins in Aqueous Solution”, Joseph J. Valente, Robert W. Payne, Mark Cornell Manning, W. William Wilson and Charles S. Henry, Current Pharm. Biotechnol. 2005, 6: 427-436.
“Self-Interaction Chromatography for Screening”, Charles S. Henry, Robert W. Payne, Joseph J. Valente, William W. Wilson, and Mark Cornell Manning, Genetic Eng. News 2005, 25: 62-63.